The emerging treatment landscape of targeted therapy in non-small-cell lung cancer

被引：487

作者：

Yuan, Min ^{[1
,2
]}

Huang, Li-Li ^{[1
,2
]}

Chen, Jian-Hua ^{[1
,3
]}

Wu, Jie ^{[3
,4
]}

Xu, Qing ^{[1
,2
]}

机构：

[1] Tongji Univ, Dermatol Hosp, Dept Oncol, Sch Med, Shanghai 200443, Peoples R China

[2] Tongji Univ, Shanghai Peoples Hosp 10, Dept Oncol, Sch Med, Shanghai 200072, Peoples R China

[3] Univ Oklahoma, Hlth Sci Ctr, Peggy & Charles Stephenson Canc Ctr, Oklahoma City, OK 73104 USA

[4] Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, Oklahoma City, OK USA

来源：

SIGNAL TRANSDUCTION AND TARGETED THERAPY | 2019年 / 4卷 / 1期

基金：

中国国家自然科学基金;

关键词：

EPIDERMAL-GROWTH-FACTOR; TYROSINE KINASE INHIBITORS; ANTI-HER3; MONOCLONAL-ANTIBODY; NIVOLUMAB PLUS IPILIMUMAB; RECEPTOR GENE-MUTATIONS; RANDOMIZED PHASE-III; OPEN-LABEL; ACQUIRED-RESISTANCE; 1ST-LINE TREATMENT; EGFR MUTATIONS;

D O I：

10.1038/s41392-019-0099-9

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Lung cancer is one of the most common cancer in the world. In 2018, there were over 2 million new cases of lung cancer and over 1.7 million deaths were attributed to lung cancer. Targeted therapy has emerged as an important mean of the disease management for patients with non-small-cell lung cancer (NSCLC). Herein, we review and analyze recent literature, discuss the targeting pathways and ongoing clinical trials in lung cancer. Chemotherapy is no longer the best available treatment for all patients. Therapeutic decisions should be guided by an understanding of the molecular features of patient's tumor tissues. The future gains will likely emerge from finding optimal ways of combining targeted therapy, immunotherapy, and chemotherapy.

引用

页数：14

共 50 条

[1] The emerging treatment landscape of targeted therapy in non-small-cell lung cancer
Min Yuan
Li-Li Huang
Jian-Hua Chen
Jie Wu
Qing Xu
Signal Transduction and Targeted Therapy, 4
[2] Targeted therapy for non-small-cell lung cancer
Rasul, K. T.
Al-Khater, A. M.
JOURNAL OF THE ROYAL COLLEGE OF PHYSICIANS OF EDINBURGH, 2010, 40 (03): : 221 - 221
[3] Targeted therapy for non-small-cell lung cancer
Belani, CP
LUNG CANCER, 2004, 45 : S7 - S7
[4] Targeted therapy in non-small-cell lung cancer
Herbst, RS
ONCOLOGY-NEW YORK, 2002, 16 (09): : 19 - 24
[5] Emerging Targeted Therapies in Non-Small-Cell Lung Cancer (NSCLC)
Mina, Syeda A.
Shanshal, Mohamed
Leventakos, Konstantinos
Parikh, Kaushal
CANCERS, 2025, 17 (03)
[6] Emerging Targeted Therapies in Advanced Non-Small-Cell Lung Cancer
Li, Shenduo
Correia, Guilherme Sacchi de Camargo
Wang, Jing
Manochakian, Rami
Zhao, Yujie
Lou, Yanyan
CANCERS, 2023, 15 (11)
[7] Targeted therapy in advanced non-small-cell lung cancer
Gettinger, Scott
SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2008, 29 (03) : 291 - 301
[8] Targeted therapy for targeted patients: Trastuzumab in adjuvant treatment of non-small-cell lung cancer
Altundag, K
Altundag, O
Morandi, P
Gunduz, M
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (06) : 1325 - 1325
[9] Erlotinib: Small-molecule targeted therapy in the treatment of non-small-cell lung cancer
Smith, J
CLINICAL THERAPEUTICS, 2005, 27 (10) : 1513 - 1534
[10] Crizotinib: A novel, targeted gene therapy for the treatment of non-small-cell lung cancer
Patel, Kejal
Abdelghany, Sam
FORMULARY, 2011, 46 (11) : 460 - +

← 1 2 3 4 5 →